Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm

Diabetes Care

Volumn 27, Issue 6, 2004, Pages 1324-1329

  Saad, Mohammed F ^a   Greco, Susan ^b   Osei, Kwame ^c   Lewin, Andrew J ^d   Edwards, Christopher ^e   Nunez, Margarita ^f   Reinhardt, Rickey R ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Jacksonville Center for Clinical Research   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d NATIONAL RESEARCH INSTITUTE   (United States)

^e Primary Care Specialists   (United States)

^f ICSL Clinical Studies   (United States)

^g NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES CONTROL; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LEUKOPENIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SINUSITIS; VOMITING; WEIGHT GAIN;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; OXAZINES; PHENYLPROPIONATES; PLACEBOS; TRIGLYCERIDES;

EID: 2542462552     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.6.1324     Document Type: Article

References (23)

1. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992
2. Betteridge DJ: Dyslipidaemia and diabetes. Pract Diabetes Int 18:201-207, 2001
3. Erkelens DW: Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol 88 (Suppl.):38J-42J, 2001.
4. Gu K, Cowie CC, Harris MI: Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21:1138-1145, 1998
5. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111). Bethesda, MD, National Institutes of Health, 2001 (NIH publ. no. 01-3670)
6. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
8. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641-651, 1998
9. Pyorala K, Perdersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620, 1997.
10. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98:2513-2519, 1998
11. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolate systolic hypertension. JAMA 276:1886-1892, 1996
12. Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, Chakrabarti R, Vikramadithyan RK, Misra P, Juluri S, Mamidi NVSR, Rajagopalan R: (-)3-[4-[2-(phenoxazin-10-yl) ethoxyl]-2-ethoxypropanoic acid [(-)DRF2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 44:2675-2678, 2001
13. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wasserman K Brand CL, Sturis J, Woldike HF, Fleckner J, Andersen AST, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM: Novel tricyclic-alkyloxyphenylporpionic acid: dual PPAR/agonists with hypolipidemic and antidiabetic activity. J Med Chem 45:789-804, 2002
14. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARα and PPARβ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15: 5336-5348, 1996
15. Auwerx J: PPAR, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999.
16. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405: 421-424, 2000.
17. Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledeius C, Hansen BF, Andersen B, Ye J-M, Sauerberg P, Wassermann K: Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 284:E841-E854, 2003
18. Ye J-M, Iglesias MA, Watson DG, Ellis B, Wood L, Jenssen PB, Sorenensen RV, Larsen PJ, Cooney GJ, Wassermann K, Kraegen EW: PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284:E531-E540, 2003
19. American Diabetes Association: Screening for diabetes (Position Statement). Diabetes Care 25 (Suppl. 1):S21-S24, 2002.
20. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride therapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23: 1605-1611, 2000
21. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: a 12-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172, 1999
22. Paolisso G, Howard BV: Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med 15: 360-366, 1998
23. Lebovitz HE, Banerji M: Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265-294, 2001